Where to Buy Retatrutide: 30 mg at $125 Beats 10 mg at $49.50

The last column is the one that decides most of this. If a channel does not publish a milligram figure and a price against a batch you can identify, no cost comparison is available to you, whatever the sticker says.

Only the first row supports the arithmetic this site runs. That is not a marketing preference, it is a consequence of what each channel publishes.

This is the channel that exists because the others do not. Suppliers sell lyophilised retatrutide as a laboratory reagent, labelled not for human consumption, in fixed strengths with a batch code and a certificate of analysis.

The structural advantage is disclosure. A listing that says 30 mg and shows a batch-matched certificate gives you a denominator, and a denominator is what turns a price into a rate. Ascension Peptides publishes two third-party certificates per batch, from Kovera Labs (batches 03-05260628 and 43-05260628, tested 26 May 2026) and MZ Biolabs (batches 03-01260229 and 43-01260229, tested 6 February 2026), and dispatches from US stock with a 2pm CST cut-off Monday to Saturday.

Domestic stock also changes the landed cost, which is part of the per-milligram figure whether or not the listing admits it. A vial dispatched inside the US carries no import VAT, no customs handling fee and no border delay. It is also worth knowing where the shipping threshold sits before you build a cart: free shipping applies over $250, and two 30 mg vials at the discounted $125.00 each come to exactly $250.00, which is on the line rather than over it. Confirm at checkout rather than assuming.

The structural limit is equally clear. Research-grade material is not held to pharmaceutical manufacturing standards, purity varies between suppliers, and the certificate describes the batch that was sampled rather than the specific vial in the box. Buying here is buying a reagent with a paper trail, not a medicine.

Bulk listings from overseas manufacturers are the origin point for a large share of what circulates downstream. They are usually quoted per gram rather than per vial, which looks dramatically cheaper until you account for what is missing.

Three things are typically absent. There is no per-vial strength, so you cannot compute a cost per milligram without weighing the material yourself on an analytical balance. There is no batch-specific third-party certificate, only a generic sheet reused across listings. And there is no dispatch guarantee, because the parcel has to clear a border, which for an unapproved compound means a genuine chance of seizure.

The honest summary is that the cheap number in this channel is not comparable to the number in channel 1. One is a price for identified material in a known quantity; the other is a price for an unmeasured mass with no chain of evidence. This page does not tell you how to move such a shipment, and there is nothing to say on that subject that is both useful and responsible.

Repackagers sell through group chats, marketplace posts and forum direct messages. The material almost always originates in channel 2, decanted into unlabelled vials with a printed sticker.

There is no arithmetic available here at all. A vial with a handwritten 10 mg on it has a claimed strength and nothing behind it, so every downstream number is fiction: the concentration after reconstitution, the units on the barrel, the cost per milligram. A calculator will still return four tidy figures, and all four will be wrong in the same direction if the labelled mass is wrong.

Payment is the second problem. Bank transfers, gift cards and peer-to-peer app payments are the usual request, and none of them carry the dispute rights a card payment does. When the recourse column of the table says none, that is what it means.

A compounding pharmacy prepares a patient-specific preparation from an approved drug or from a bulk drug substance that sits on an approved list. Retatrutide is neither. It has no US marketing authorisation and it is not an eligible bulk substance, so a 503A pharmacy or 503B outsourcing facility has no lawful basis to compound it.

This is worth stating clearly because the compounded semaglutide and tirzepatide market has made people assume every incretin is obtainable this way. It is not, and the difference is not a technicality. A compounder working from an approved reference product is in a different legal position from one making an investigational molecule that has never been approved anywhere. The FDA sets out the framework and the limits in its compounding guidance.

If a site advertises compounded retatrutide, treat it as a signal about the seller rather than about the product. Either the label is not retatrutide, or the operation is outside the compounding framework entirely.

Telehealth weight-management services prescribe approved medicines: semaglutide and tirzepatide, and in some markets liraglutide. They cannot prescribe retatrutide, because a prescription is an instruction to dispense an approved product and no approved retatrutide product exists.

What a clinic can offer is the approved alternative, and the pricing there works on a completely different unit. Pens are priced per device and per dose tier rather than per milligram, which is why a comparison between a clinic quote and a research vial is not a like-for-like comparison of anything. Our tirzepatide cost guide works through how those quotes are structured, and our tirzepatide reference page covers the vial arithmetic on that compound.

Enrolment in the Phase 3 TRIUMPH programme is the only route to clinically supervised retatrutide, and trial sites and eligibility criteria are listed on ClinicalTrials.gov.

Inside channel 1, the comparison is straightforward: divide the discounted price by the vial strength. $49.50 ÷ 10 mg gives $4.95 per mg. $125.00 ÷ 30 mg gives $4.17 per mg. The 30 mg vial is about 16% cheaper for the same milligram.

Where people go wrong is comparing cost per syringe unit instead, which changes with the diluent volume and therefore compares nothing.

A third division is worth running at the same time, and it also ignores the water. Draws per vial is vial strength divided by draw size: a 30 mg vial supports 15 draws of 2 mg, while a 10 mg vial supports 5. Buying the larger vial buys three times the material for 2.53 times the money, which is the 16% per-milligram gap restated as a supply question.

Read the last two columns together. Cost per unit halves when you double the water, because a unit is a volume marking of 0.01 mL and nothing else. Cost per milligram does not move at all, because water is not in that equation. Rows two and four both cost $0.25 per unit and are $0.78 per milligram apart.

That is the whole case for pricing in milligrams. Our peptide calculator guide explains the four divisions in detail, the syringe measurement guide covers reading the barrel, and the reconstitution calculator will run any vial and diluent combination you enter.